Striverdi Respimat Side Effects

The safety of STRIVERDI RESPIMAT has been evaluated in placebo- and active-controlled, parallel-group and cross-over clinical trials in overall 4,167 patients with COPD. A total of 1,927 patients with COPD received the target dose of 5 microgram olodaterol.
Side effects of STRIVERDI RESPIMAT were primarily identified from data obtained in 4 placebo-controlled, parallel-group, long-term treatment (48 weeks) clinical trials in COPD patients. Two of these trials were also active-comparator controlled.
Infections and infestations: Nasopharyngitis, Upper respiratory tract infection, Bronchitis, Urinary tract infection.
Nervous system disorders: dizziness.
Vascular disorders: hypertension.
Skin and subcutaneous disorders: rash.
Musculoskeletal and connective tissue disorders: Arthralgia, Back pain.
Respiratory, thoracic, and mediastinal disorders: Cough.
Gastrointestinal disorders: Diarrhoea.
Occurrence of rash may be considered a hypersensitivity reaction with STRIVERDI RESPIMAT; as with all topical absorbed medication, other hypersensitivity reactions may develop.
Olodaterol is a member of the therapeutic class of long-acting beta₂-adrenergic agonists. Therefore, the occurrence of undesirable effects related to the beta-adrenergic agonist class should be taken into consideration, such as tachycardia, arrhythmia, palpitations, myocardial ischaemia, angina pectoris, hypertension or hypotension, tremor, headache, nervousness, insomnia, dizziness, dry mouth, nausea, muscle spasms, fatigue, malaise, hypokalemia, hyperglycemia, and metabolic acidosis.